Synthetic Genomics

Synthetic Biology Markets, 2026: Tissue Regeneration, Biofuel, Consumer Care, Food & Agriculture, Environmental - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021

Factors such as the increasing demand for synthetic genes and synthetic cells, wide range of applications of synthetic biology, declining cost of DNA sequencing and synthesizing, increasing R&D funding and initiatives in synthetic biology, and increasing investments in the market are propelling the growth of this market.

Key Points: 
  • Factors such as the increasing demand for synthetic genes and synthetic cells, wide range of applications of synthetic biology, declining cost of DNA sequencing and synthesizing, increasing R&D funding and initiatives in synthetic biology, and increasing investments in the market are propelling the growth of this market.
  • However, rising biosafety, biosecurity, and ethical concerns related to synthetic biology is likely to hamper the growth of this market.
  • On the basis of tool, the synthetic biology market is broadly segmented into oligonucleotides & synthetic DNA, enzymes, cloning technology kits, synthetic cells, chassis organisms, and xeno-nucleic acids.
  • Based on application, the synthetic biology market is segmented into medical applications, industrial applications, food & agriculture, and environmental applications.

Twist Bioscience Announces Fireside Chat and Presentation at BIO Digital

Retrieved on: 
Monday, June 14, 2021

Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that CEO Emily Leproust will participate in a fireside chat at the BIO Digital conference being held virtually from June 10-11 and 14-18, 2021.

Key Points: 
  • Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that CEO Emily Leproust will participate in a fireside chat at the BIO Digital conference being held virtually from June 10-11 and 14-18, 2021.
  • The presentation can be accessed from the BIO Digital website at https://www.bio.org/events/bio-digital/sessions/806568 .
  • Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
  • Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery.

Synthetic Biology Market worth $30.7 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, May 24, 2021

However, biosafety, biosecurity, and ethical concerns related to synthetic biology would hamper the growth of this market.

Key Points: 
  • However, biosafety, biosecurity, and ethical concerns related to synthetic biology would hamper the growth of this market.
  • The oligonucleotides and synthetic DNA segment accounted for the largest share of the tool segment in the synthetic biology market in 2020.
  • On the basis of tool, the market is broadly segmented into oligonucleotides & synthetic DNA, enzymes, cloning technology kits, synthetic cells, chassis organisms, and xeno-nucleic acids.
  • In 2020, medical applications segment accounted for the largest share of synthetic biology market.

Synthetic Biology Market worth $30.7 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, May 24, 2021

However, biosafety, biosecurity, and ethical concerns related to synthetic biology would hamper the growth of this market.

Key Points: 
  • However, biosafety, biosecurity, and ethical concerns related to synthetic biology would hamper the growth of this market.
  • The oligonucleotides and synthetic DNA segment accounted for the largest share of the tool segment in the synthetic biology market in 2020.
  • On the basis of tool, the market is broadly segmented into oligonucleotides & synthetic DNA, enzymes, cloning technology kits, synthetic cells, chassis organisms, and xeno-nucleic acids.
  • In 2020, medical applications segment accounted for the largest share of synthetic biology market.

Twist Bioscience Supports the Engineering Biology Research Consortium as it Publishes Statement of Ethics

Retrieved on: 
Thursday, May 13, 2021

b'Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced its support of the Engineering Biology Research Consortium (EBRC) and its Statement of Ethics in Engineering Biology Research .

Key Points: 
  • b'Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced its support of the Engineering Biology Research Consortium (EBRC) and its Statement of Ethics in Engineering Biology Research .
  • As with many other rapidly growing and highly impactful technologies, the long-term implications of this innovative research require forward-thinking guidelines and ethical frameworks to support responsible use.
  • The EBRC Statement of Ethics helps to provide additional guidance to our community, which we welcome and support.\xe2\x80\x9d\nTwist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
  • Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.\nThis press release contains forward-looking statements.

Twist Bioscience to Present at Upcoming Virtual Conferences

Retrieved on: 
Friday, February 19, 2021

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming virtual investor conferences:

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming virtual investor conferences:
    SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26; fireside chat at 11:20 a.m. Eastern Time.
  • Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
  • Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery.
  • Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Twist Bioscience to Present at the 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 4, 2021

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11th at 5:20 p.m. Eastern Time.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11th at 5:20 p.m. Eastern Time.
  • A replay of the presentations will be archived for a period of 30 days following the conclusion of the live event.
  • Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
  • Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Twist Bioscience to Expand Commercial Capabilities with Factory of the Future

Retrieved on: 
Tuesday, December 22, 2020

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced plans to expand its manufacturing and commercial capabilities with the addition of the Factory of the Future just outside of Portland, Oregon in Wilsonville.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced plans to expand its manufacturing and commercial capabilities with the addition of the Factory of the Future just outside of Portland, Oregon in Wilsonville.
  • The 110,000-square-foot facility is expected to become operational in 2022 and potentially bring up to 400 jobs to the region over several years.
  • Leproust continued, We are expanding our customer base and ramping production of our products at an exceptional rate.
  • Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.

CATALOG Hires Key Scientists, Names Advisory Board to Advance DNA Computing and Storage

Retrieved on: 
Monday, December 14, 2020

To solve this problem, CATALOG is using synthetic DNA to convert the sequences of 0's and 1's used in traditional computing into synthetic DNA sequences of A's, C's, T's, and G's.

Key Points: 
  • To solve this problem, CATALOG is using synthetic DNA to convert the sequences of 0's and 1's used in traditional computing into synthetic DNA sequences of A's, C's, T's, and G's.
  • Key members with extensive academic, scientific, and government lab expertise joining the advisory board include:
    Anne Condon, Ph.D. and Professor at the University of British Columbia.
  • "CATALOG is at a critical point in our growth with a vision for DNA for computing and storage," said CATALOG CEO and Co-founder Hyunjun Park.
  • Founded in 2016 by MIT scientists, CATALOG is the first company to have developed a solution to make DNA data storage and computing commercially viable.

Twist Bioscience to Present at the Stifel 2020 Virtual Healthcare Conference

Retrieved on: 
Tuesday, November 10, 2020

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16 at 4:40 p.m. Eastern Time.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16 at 4:40 p.m. Eastern Time.
  • A replay of the presentation will be archived for a period of 90 days following the conclusion of the live event.
  • Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
  • Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.